Interpreting Efficacy Data and Assessing Risk-Benefit in a Curative-Intent Population

This segment turns to the clinical trial evidence supporting adjuvant CDK4/6 inhibition, with the faculty examining invasive disease-free survival outcomes from monarchE and the consistency of benefit across clinically relevant subgroups including menopausal status, tumor size, tumor grade, and nodal burden. The panel discusses how extended follow-up has reinforced confidence in these agents, noting that the separation between treatment curves has been sustained beyond the completion of therapy, and considers what additional long-term data may bring for ribociclib. The conversation then shifts to the challenge of framing risk and benefit in a curative-intent population, where patients are typically asymptomatic and may question the need for further treatment after surgery. The faculty emphasize patient education around the rationale for adjuvant therapy and the goal of preventing distant recurrence. The segment closes with a candid exchange on treatment discontinuation, contrasting rates reported in clinical trials with real-world experience and underscoring the role of attentive clinical follow-up and dose adjustment in keeping patients on therapy.